Podcasts about Median

Don tackles a stack of listener questions in this rapid-fire Friday Q&A, covering what a financial plan should cost, how tipping might work in a cashless future, and how to fine-tune a retirement portfolio with Avantis funds. He also addresses important estate planning steps after a death, how to use QCDs with inherited IRAs, and whether AUM fees are worth it compared to hourly planners. Along the way, he reflects on why he still manages his own money—and maybe shouldn't. 0:04 Intro to Friday Q&A and how listener questions are selected 2:12 What should a detailed retirement plan cost? Median price range explained 4:33 How will we tip in a cashless society? From bellboys to Bitcoin to Apple Pay 7:39 Listener portfolio check: 85% AVGE, 10% AVUV, 5% AVDV—too tilted? 11:36 Credit after death: Should an executor notify the credit bureaus? Yes—and how 13:45 Inherited IRA RMD workaround: Can QCDs help avoid taxes before age 70½? 17:02 AUM fees vs. flat-fee advisors: Is paying more for more assets fair? 25:51 Why Don still manages his own money (for now)—inertia, taxes, and habits Learn more about your ad choices. Visit megaphone.fm/adchoices

최근 실시된 글로벌 조사에서 호주가 성인 1인당 중간 재산(Median wealt) 기준 세계 2위를 기록했습니다.

Mathias ist Vorstandsvorsitzender von Axel Springer, Medienmanager, Autor und Journalist. Und vor allem ist er laut ChatGPT auf Platz 2 der mächtigsten Medienmänner weltweit. Ich wollte von ihm wissen, wie seine Biografie ihn geprägt hat, welche Werte er mit Freiheit verbindet und wie sich das eigene Verhältnis zu Geld verändert, wenn man Milliardär ist. Außerdem habe ich mich gefragt, was seine heutige Sicht auf den Fall Julian Reichelt ist. Wir sprechen über Macht, Vertrauen, Zweckpessimismus, es geht um Widerstand, Mut, Risiko, Diskussionskultur und familiäre Werte. WERBEPARTNER & RABATTE: https://linktr.ee/hotelmatze MEIN GAST: https://ullstein.de/urheberinnen/mathias-doepfner DINGE: Nile Rodgers - Le Freak: https://thalia.de/shop/home/artikeldetails/A1020984635 Benjamin von Stuckrad-Barre - Noch wach?: https://thalia.de/shop/home/artikeldetails/A1064678458 Maximilian Frisch - Produktion Torben Becker - Redaktion Lena Rocholl - Redaktion Mit Vergnügen - Vermarktung und Distribution MEIN ZEUG: Mein neues Fragenset: https://beherzt.net/liebe Mein neues Buch: https://bit.ly/3cDyQ18 Die Hotel Matze Suite bei Apple: https://apple.co/43V3hGq Die Hotel Matze Suite bei Spotify: https://spoti.fi/3U3ZySC Wunschgäste bitte in die Kommentare: https://apple.co/2RgJVH6 Mein Newsletter: https://matzehielscher.substack.com/ TikTok: https://tiktok.com/@matzehielscher Instagram: https://instagram.com/matzehielscher LinkedIn: https://linkedin.com/in/matzehielscher/ YouTube: https://bit.ly/2MXRILN Twitter: https://twitter.com/hotelmatze1 Mein erstes Buch: https://bit.ly/39FtHQy Mein erstes Fragenset: https://beherzt.net/matze

MDJ Script/ Top Stories for June 6th Publish Date:  June 6th    Commercial: From the BG AD Group Studio, Welcome to the Marietta Daily Journal Podcast.    Today is Friday, June 6th and Happy Birthday to Tommie Smith I’m Keith Ippolito and here are the stories Cobb is talking about, presented by Times Journal New $50,000 Median to Drive Safety on Fairground Street Attempted Carjacking Suspect Held at Gunpoint by Civilian, Arrested in Marietta Kennesaw’s Salute to America is July 3 Plus, Leah McGrath from Ingles Markets on controlling your sweet tooth All of this and more is coming up on the Marietta Daily Journal Podcast, and if you are looking for community news, we encourage you to listen and subscribe!  BREAK: TOP TECH MECHANICAL STORY 1: New $50,000 Median to Drive Safety on Fairground Street Marietta is enhancing road safety with a new median on Fairground Street near Haley Street. The $50,000 project, set to finish next week, aims to prevent U-turns that have caused accidents and traffic issues. The median will allow only left turns off Fairground Street, with 200 feet of median and 115 feet of curb being installed. Signage will alert drivers to the changes, ensuring smoother and safer traffic flow. STORY 2: Attempted Carjacking Suspect Held at Gunpoint by Civilian, Arrested in Marietta A carjacking suspect, Rico Riley, was arrested in Marietta after a witness, Gary Edwards, intervened and held him at gunpoint. Riley allegedly attempted to steal two cars at a Chevron gas station on Franklin Gateway. He first fought a woman for her car keys, then tried to carjack a second vehicle with a family inside. Edwards intervened both times, ultimately detaining Riley until police arrived. Riley faces multiple felony charges, including attempted armed robbery and child cruelty, and is held without bond. Marietta Police commend Edwards but urge witnesses to prioritize safety and call 911 in such situations. STORY 3: Kennesaw’s Salute to America is July 3 Kennesaw's annual Independence Day celebration, **Salute to America**, takes place July 3 from 6–10 p.m. in downtown Kennesaw. The free event features live music, food vendors, family activities, and a fireworks finale at 9:30 p.m. Performances include Tripp’n at 6 p.m., Girls Night Out at 7 p.m., and Guardians of the Jukebox at 8 p.m. Kids can enjoy ticketed inflatables, and food and drinks will be available for purchase. Reserved seating is $20, with reservations at kennesawjuly3.com. Tobacco and e-cigarettes are prohibited, and the event may be rescheduled for bad weather. We have opportunities for sponsors to get great engagement on these shows. Call 770.799.6810 for more info.  Break: Ingles Markets 2 STORY 4: Update: Asylum Seeker Married to Alpharetta Man Released on Bond Colombian asylum seeker Daniela Landin, 24, was released on a $10,000 bond after nearly a month in ICE custody. Married to Alpharetta resident Richard Landin, she fled gang violence in Colombia and sought asylum last year, though her initial request was denied and is under appeal. ICE detained her in May, citing an issue with her ankle monitor, despite it functioning properly. Her bond was granted after a delayed hearing, with the judge convinced of her sincerity and low flight risk. The couple, unable to fly due to her lack of ID, is driving back to Georgia, relieved to reunite. STORY 5: OUT AND ABOUT: 5 Things to Do This Weekend in Cobb County — June 6 - 8 This weekend in Cobb County offers a variety of events: Marietta Square hosts its free Art Walk Friday from 5-9 p.m., showcasing local art alongside shopping and dining. The BLADE Show at Cobb Galleria Centre runs Friday-Sunday, featuring unique blades and collectibles, with tickets starting at $30. The Kennesaw Grand Prix 5K kicks off Saturday at 8 a.m., followed by a post-race party. The Strand Theatre presents "Grease" with showtimes through June 22, and Swift-Cantrell Park in Kennesaw screens "Moana 2" Saturday at 8:15 p.m., with pre-movie activities starting at 6 p.m. Break: And now here is Leah McGrath from Ingles Markets on controlling your sweet tooth We’ll have closing comments after this. Break: TIDWELL TREES Signoff-   Thanks again for hanging out with us on today’s Marietta Daily Journal Podcast. If you enjoy these shows, we encourage you to check out our other offerings, like the Cherokee Tribune Ledger Podcast, the Marietta Daily Journal, or the Community Podcast for Rockdale Newton and Morgan Counties. Read more about all our stories and get other great content at mdjonline.com Did you know over 50% of Americans listen to podcasts weekly? Giving you important news about our community and telling great stories are what we do. Make sure you join us for our next episode and be sure to share this podcast on social media with your friends and family. Add us to your Alexa Flash Briefing or your Google Home Briefing and be sure to like, follow, and subscribe wherever you get your podcasts. Produced by the BG Podcast Network Show Sponsors: www.ingles-markets.com tidwelltrees.com toptechmech.com #NewsPodcast #CurrentEvents #TopHeadlines #BreakingNews #PodcastDiscussion #PodcastNews #InDepthAnalysis #NewsAnalysis #PodcastTrending #WorldNews #LocalNews #GlobalNews #PodcastInsights #NewsBrief #PodcastUpdate #NewsRoundup #WeeklyNews #DailyNews #PodcastInterviews #HotTopics #PodcastOpinions #InvestigativeJournalism #BehindTheHeadlines #PodcastMedia #NewsStories #PodcastReports #JournalismMatters #PodcastPerspectives #NewsCommentary #PodcastListeners #NewsPodcastCommunity #NewsSource #PodcastCuration #WorldAffairs #PodcastUpdates #AudioNews #PodcastJournalism #EmergingStories #NewsFlash #PodcastConversations See omnystudio.com/listener for privacy information.

A new track by DJ Habett from the album "Nach Mitternacht" (2025-06-05). Tags: Triphop, Bigbeat, Energy, Median, Groove, References, Dawn, Theme CC(by). Production notes: Recorded the day after. Lazy mastering on a second take on the reels. Felt like the right thing to do but forgot the inital sample.

See omnystudio.com/listener for privacy information.

Median house prices hit $1 million across capital cities, government taxes blamed for reigniting Australia’s tobacco wars. Plus, Erin Patterson takes the stand in her mushroom poisoning murder trial.See omnystudio.com/listener for privacy information.

The latest PropTrack Home Price Index has revealed that Brisbane’s median house price has reach $998,000. The data has shown that the main reasons for the increase are labour shortages, supply chain disruptions and soaring prices for essential materials. Housing Industry Association Managing Director Jocelyn Martin told Peter Fegan on 4BC Breakfast, "The problem is we build 160, 170,000 new homes in Australia every year." "If we were actually really going to make a difference in terms of our approach to building and housing and climate, it would be the 11 million other homes that we really should be looking at." "We're getting a diminishing return from that National Construction Code and the seven star [rating]," Mrs Martin said.See omnystudio.com/listener for privacy information.

This week in Canadian real estate, we saw a rare move toward improving housing affordability—but is it too little, too late?The federal government has announced a GST rebate for first-time home buyers purchasing new homes valued up to $1.5 million. Homes under $1 million will be eligible for a full GST rebate—as much as $50,000—while homes between $1 million and $1.5 million receive a partial rebate. The government claims this will help reduce upfront costs for young Canadians and spur new housing construction. But when you consider that only 10–20% of Canada's roughly 300,000 annual first-time buyers purchase new homes, this measure will actually benefit just 30,000 to 60,000 people nationwide. A step in the right direction? Yes. A scalable solution to affordability? Probably not.And while tax relief is welcome, the bigger issue continues to loom: the soaring cost of construction. Since 2017, Canada's Building Construction Price Index has jumped 90%, nearly doubling costs in just eight years—largely driven by pandemic-era supply chain shocks and inflation. This means even with incentives, developers are unlikely to hit federal housing targets, and pre-sale markets will remain fragile as margins thin and feasibility erodes.We also take a deep dive into Canada's residential mortgage debt, which now totals over $2.42 trillion—including $2.07 trillion in mortgages and $350 billion in HELOCs. That's nearly $370,000 in average mortgage debt across the 6.5 million homes with outstanding loans. With an average amortization of 20 years and today's fixed rates around 4.14%, the average monthly mortgage payment comes in at $2,256. That's barely more than Canada's average rent of $2,109, showing how thin the line between renting and owning has become for many households.Meanwhile in the U.S., delinquency rates on car loans have hit record highs—over 6.5% of borrowers are now more than 60 days behind. It's a stark indicator of mounting financial stress, and one that could spill over into the broader economy, potentially triggering interest rate cuts and even recessionary pressure stateside. A U.S. slowdown almost always influences Canada, especially when it comes to monetary policy.We also zoom out and look at G7 home price trends, and the results are jaw-dropping. Since 1985, Canada leads the G7 in inflation-adjusted home price appreciation—up 360%. That's even after an 18% national correction from peak pricing. For comparison, the UK is up 340%, the U.S. 220%, while Japan's prices have actually fallen 30%. The data paints a picture of just how extreme Canada's housing market has become over time—and how hard it may be to “normalize.”And finally, we preview next week's Bank of Canada interest rate decision. As of May 26th, odds are now sitting at 70% that there will be no cut, despite growing calls for relief. With inflation data holding steady and economic signals mixed, the BoC remains cautious.In our mini market update: Vancouver has just crossed 18,000 active listings—the most in 12 years—while May sales are on track to be the lowest ever recorded for the month, even as prices spike. Median prices are now within 1% of all-time highs, and average prices are up over $50,000 in just 30 days. It's a paradoxical moment: high supply, low sales, rising prices. Welcome to 2025. _________________________________ Contact Us To Book Your Private Consultation:

Ivan Puopolo Median Batman | #neuvottelija 334. Helsingin Sanomat haastatteli Ivan Puopoloa artikkeliin Puopolon kaksi puolta - vakavastiotettava MTV:n aamutelevision haastattelija ja Batmaninä toimiminen Ivan Puopolon tube-isäntänä. Sami ja Ivan keskustelevat Suomen mielipiteiden kirjosta ja mitä saa sanoa missäkin mediassa. Oikeisto- ja vasemmistomielipiteet ovat kuin puurot ja vellit, jotka eivät saa mennä sekaisin.00:00 Faktantarkastus $488 Tesla oikein, Ivan Puopololle olut!02:02 Puopolo mediassa: Maikkarin aamut vs. illan tubekanava02:40 Kaupallinen yhteistyö, Gasgrid Finland The Changers ja Lauri Ratia https://open.spotify.com/show/19XFAVLLrQP5z8KQRLTGE7?si=2378dfaba34a4f5303:18 Helsingin Sanomien artikkeli - Puopolon kaksi puolta05:30 Työnantaja vai asiakas – Tomi Einosen särmä vastaus11:28 Pitkän haastattelun leikkaus ja toimitukselliset valinnat14:40 Mielipiteet, objektiivisuus ja yleisön luottamus16:36 Rehellisyys vs. kancelointikulttuuri18:27 Kaupallisten yhteistyöiden odotukset20:24 Toimittajan rooli ja neutraaliuden myytti22:15 Jussi Halla-aho-esimerkki ja journalistinen vastuu23:45 Julkaisijan juridinen ja eettinen vastuu25:42 Propagandan tunnistaminen ja määrittely27:21 Politiikan viestintä ja lukijan manipulointi28:57 Kokemus median yksipuolisuudesta ja faktavirheistä30:51 Vale vai harhaanjohtaminen – rajankäynti32:36 Voisiko Kalevi Sorsa -säätiön ekonomisti irrottautua roolista34:19 Esimerkkejä medialukutaidon merkityksestä36:06 Venäjä-analyysi ja johdonmukaisuuden ymmärtäminen37:51 Analyysi vs. paheksunta toimittajan työssä39:37 Median monoliittisuus ja kanavien leimaaminen41:20 Ivan Putin ja Venäjän strateginen kulttuuri43:22 Arvokonflikti Venäjän ja lännen välillä45:01 Puhe länsimaisesta lässytyksestä ja arvoista47:13 Kotimaiset poliittiset podcastit ja niiden rajallisuus48:44 Huipulle pääsy ja näkökulmien kapeneminen50:20 Vasemmiston lähtö X:stä ja julkisen tilan kutistuminen52:13 Kriisipalaveriesimerkki ja somepaine53:55 Twitter-algoritmi, näkyvyys ja vasemmistoyleisö55:46 Lehdistön painotukset ja edunsaajien puhevalta57:49 Ideologinen laiskuus ja valtion budjettipuhe59:28 Lisää mediapersoonia sivukanavien kautta?#neuvottelija Sisäpiirissä Ivan Puopolon Viikon viisasteluklubi, Tere ja OnniKatso Sisäpirijaksot ja tue Samiahttps://www.youtube.com/channel/UCRI34L9OtDJuZpaWicbNXzg/join#neuvottelija Sami Miettinen

Pack your bags! The Median home sales prices in Logan, Utah dropped 5.8% year to $410,900. Russel Faucett, Owner of the Stern of Omada Real Estate joins the show to explain what is happening in Logan to make home prices a more affordable option.

Češi považují za nejvážnější problém českého školství nedostatečné kapacity mateřských škol. V průzkumu agentury Median pro Radiožurnál a Český rozhlas Plus se na tom shodlo začátkem května přes 80 procent z 1000 respondentů. Co by s tím udělali politici? „Není to o tom, že by se nestavělo. Pomohla by větší koordinace obcí, které jsou ve své bezprostřední blízkosti. Stálo by za to i odbourat byrokracii, aby mohly vznikat dětské skupiny,“ říká Matěj Gregor (Motoristé sobě).

Téměř všichni Češi chtějí, aby škola děti připravila na výzvy budoucnosti a naučila je kritickému myšlení, uvádí průzkum agentury Median pro Radiožurnál a Český rozhlas Plus. Jak připravit děti na měnící se svět? „Bylo by lepší, kdybychom se vrátili k jednotným osnovám a měli více pod kontrolou, co se ve školách vyučuje. Rámcové vzdělávací programy jsou nekoncepční a dávají možnost zasahovat do výuky třeba různým neziskovým organizacím,“ říká Petra Prokšanová (Stačilo!).

Posloucháte rádi Ptám se já? I letos pro nás i další pořady z dílny Seznam Zpráv můžete hlasovat v anketě Podcast roku. Moc děkujeme za podporu a přejeme příjemný poslech této epizody. --Motoristé sobě, největší překvapení loňských eurovoleb, by rádi zopakovali svůj úspěch i ve volbách do Sněmovny. Na voliče zafungoval fenomén jejich hlavní tváře Filipa Turka. Podle průzkumů ale strana ztrácí. Jak chce otočit trend? Hostem Ptám se já byl předseda strany Motoristé sobě Petr Macinka. Motoristé tento týden vyjíždějí do regionů za voliči se svou tour s názvem Opravíme stát. Podle lídra Petra Macinky je třeba opravit chyby napáchané dosavadními elitami, které způsobily, že motor se zadrhl. Strana například slibuje držet nízké výdaje státu a nezvyšovat daně nebo stavět se proti „ideologickým agendám“.Kampaň Motoristů podpoří i europoslanec, čestný předseda a hlavní tvář strany Filip Turek. Ten pravidelně vyvolává kontroverze, nedávno například svou příliš rychlou jízdou. Média teď navíc zpochybnila jeho pověst závodníka. Zda bude sám Turek do Poslanecké sněmovny kandidovat, ještě neoznámil. Narozdíl od loňských evropských voleb, kdy strana ve spolupráci s hnutím Přísaha získala dva mandáty, půjde do sněmovních voleb samostatně. Její ambicí je podle Macinky stát se součástí příští vládní koalice. Podle posledního volebního modelu agentury Median by se Motoristé do dolní komory parlamentu dostali a dokonce zaznamenali růst ze šesti sedm procent. Průzkumy dalších agentur ale ukazují spíše na opačný trend. Podle STEM Motoristům klesla podpora na 3,6 procenta. Na potřebnou pětiprocentní hranici pro vstup do Sněmovny by nedosáhli ani podle dat NMS. Jak chtějí Motoristé opravit Česko? Na koho chtějí v kampani mířit? A proč Filip Turek váhá s oznámením, zda bude kandidovat? --Podcast Ptám se já. Rozhovory s lidmi, kteří mají vliv, odpovědnost, informace.Sledujte na Seznam Zprávách, poslouchejte na Podcasty.cz a ve všech podcastových aplikacích.Archiv všech dílů najdete tady. Své postřehy, připomínky nebo tipy nám pište prostřednictvím sociálních sítí pod hashtagem #ptamseja nebo na e-mail: audio@sz.cz.

Welcome to the latest Bay Area Housing Market Update for May 2025!

Welcome to The Gwart Show! Today, Ethereum bull Ryan Berckmans joins us to dissect Ethereum's current strategy and why he believes it remains on the right path despite recent challenges. Ryan explains the "hub and spokes" L1+L2 model, arguing that communication failures—not technical problems—damaged ETH sentiment. He breaks down why L2 growth combined with L1 scaling will drive Ethereum toward becoming a multi-trillion dollar asset, how blob fees will generate significant revenue, and why Solana's success doesn't threaten Ethereum's long-term dominance in the institutional market. Subscribe to the newsletter! https://newsletter.blockspacemedia.com # Notes: • L2s like Base hit 100M+ in Bitcoin-backed loans • World L2 has 12M verified humans with 25M accounts • Ethereum plans to scale to 48 blobs per block • Current blob usage at ~80% full (2.4 per block) • Rollups may pay ~30% of revenue for blob space • Median user fees could remain at ~$0.01 with scale Timestamps: 00:00 Start 00:22 Who is Ryan B? 01:12 Why bullish on ETH? 06:38 Failure to communicate 11:01 Is this a pivot? 18:32 Justin Drake is bad at PR 24:31 Lido 28:05 Solo staking 31:50 It's all SOL's fault 33:03 Vitalik changing narratives 35:14 Thoughts on Solana 44:03 WHY NGU now? 48:50 Blobs need to pay up

Welcome to the "Saturday Morning Golf Stat" from the Hack it Out Golf Podcast. You've missed the green in the rough, but you're still hoping to get up and down and save a score. How far are you likely to end up from the hole when you're 35 yards away and in the rough? In this episode, Lou quizzes Mark and Greg on median distance by handicap. Afterwards, they reiterate why you need to be aware of what a good shot really is—and how expectation management can increase your performance on the course. Each of these will be a mini-episode (10-15 minutes long) about an interesting golf stat. We will discuss what you can learn, and most importantly, how you can apply this on the golf course to lower your scores and lower your handicap. Listen on your drive to the golf course or over your Saturday morning coffee! Data is sourced from Arccos Golf. They have over 1 BILLION shots in their database.  Check them out at: https://www.arccosgolf.com/  Use code DATALOU15 for 15% off! Learn more about your ad choices. Visit megaphone.fm/adchoices

Picking up from their previous discussion on the rise of million-dollar HDBs, George, Alfred, and Joan from PropertyLimBrothers return to discuss what buyers should watch for in 2025. They talked how current price trends—defined by ongoing cooling measures—are influencing buying power and long-term plans. Find out what they think about why prices in the OCR have surged, what's fuelling demand in the RCR, and how new launches are being priced island-wide.   Also, Joan shares why she believes it's better to act early, while Alfred outlines the logic behind starting with a two-bedder. They also touch on how to manage FOMO, read the shifts in policy, and stay grounded despite market noise. If you're trying to decide whether to buy, wait, or pivot—this episode offers clear, timely insight to help guide your next move.   00:00 Introduction 00:40 HDB price trend 03:09 Age always affects you 05:00 Interest rate will drop? 09:00 Future cooling measure scenario 12:22 Median age of buyers (New Private Home) 14:30 Advice for first time home owners 17:58 Median profit 18:30 Prices of private property market 25:42 RCR having more demand 28:30 Hottest new launches today 29:30 New Launch important things to take note 36:42 Upcoming New Launches 40:50 Closing 41:55 Outtakes

Host Dr. Davide Soldato and guest Dr. Harriet Kluger discuss the JCO article "Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, Medical Oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO author Dr. Harriet Kluger. Dr. Kluger is a professor of medicine at Yale School of Medicine, Director of the Yale SPORE in Skin Cancer, and an internationally recognized expert in immuno-oncology for melanoma and renal cell carcinoma. She leads early-phase and translational trials that pair novel immunotherapies with predictive biomarkers to personalized care. Today, Dr. Kluger and I will be discussing the article titled "Phase 2 Trial of Pembrolizumab in Combination with Bevacizumab for Untreated Melanoma Brain Metastases." In this study, Dr. Kluger and colleagues evaluated four cycles of pembrolizumab plus the anti-VEGF antibody bevacizumab followed by pembrolizumab maintenance in patients with asymptomatic non-hemorrhagic melanoma brain metastases that had not previously received PD-1 therapy. Thank you for speaking with us, Dr. Kluger. Dr. Harriet Kluger Thank you for inviting me. The pleasure is really all mine. Dr. Davide Soldato So to kick off our podcast, I just wanted to ask if you could outline a little bit the biological and clinical rationale that led you to test this type of combination for patients with untreated brain metastases from metastatic melanoma. Dr. Harriet Kluger Back in approximately 2012, patients who had untreated brain metastases were excluded from all clinical trials. So by untreated, I mean brain metastases that had not received local therapy such as surgery or radiation. The reason for it was primarily because there was this fear that big molecules wouldn't penetrate brain lesions because they can't pass the blood-brain barrier. Turns out that the blood-brain barrier within a tumor is somewhat leaky and drugs sometimes can get in there. When PD-1 inhibitors were first identified as the next blockbuster class of drugs, we decided to conduct a phase 2 clinical trial of pembrolizumab monotherapy in patients with untreated brain metastases. We actually did it also in lung cancer, and we could talk about that later on. Responses were seen. The responses in the brain and the body were similar. They were concordant in melanoma patients. Now, at approximately that time, also another study was done by the Australian group by Dr. Georgina Long, where they did a randomized trial where patients who didn't require immediate steroid therapy received either nivolumab alone or nivolumab with ipilimumab, and the combination arm was substantially superior. Subsequently, also, Bristol Myers Squibb also conducted a large phase 2 multicenter trial of ipilimumab and nivolumab in patients with untreated brain metastases. And there, once again, they saw that the responses in the brain were similar to the responses in the body. Now, somewhere along the line there, we completed our anti-PD-1 monotherapy trial. And when we looked at our data, we still didn't have the data on ipilimumab and nivolumab. And our question was, “Well, how can we do better?” Just as we're always trying to do better. We saw two really big problems. One was that patients had a lot of perilesional edema. And the other one was that we were struggling with radiation necrosis in lesions that were previously Gamma Knifed. The instance of radiation necrosis was in excess of 30%. So the rationale behind this study was that if we added bevacizumab, maybe we could treat those patients who had some edema, not requiring steroids, but potentially get them on study, get that PD-1 inhibitor going, and also prevent subsequent radiation necrosis. And that was the main rationale behind the study. We had also done some preclinical work in mouse models of melanoma brain metastases and in an in vitro blood-brain barrier model where we showed that bevacizumab, or anti-VEGF, really tightens up those leaky basement membranes and therefore would be very likely to decrease the edema. Dr. Davide Soldato Thank you very much for putting in context the combination. So this was a phase 2 trial, and you included patients who had at least one lesion, and you wanted lesions that were behind 5 and 20 millimeters. Patients could be included also if the brain metastasis was higher in dimension than 20 millimeters, but it had to be treated, and it was then excluded from the evaluation of the primary objective of the trial. So regarding, a little bit, these characteristics, do you think that this is very similar to what we see in clinical practice? And what does this mean in terms of applicability of these results in clinical practice? Dr. Harriet Kluger So that's an excellent question. The brain metastasis clinical research field has somewhat been struggling with this issue of inclusion/exclusion criteria. When we started this, we showed pretty clearly that 5 to 10 millimeter lesions, which are below the RECIST criteria for inclusion, are measurable if you use MRIs with slices that are 1 to 2 millimeters. Most institutions in the United States do use these high-resolution MRIs. I don't know how applicable that is on a worldwide scale, but we certainly lowered the threshold for inclusion so that patients who have a smattering of small brain metastases would be eligible. Now, patients with single large brain metastases, the reason that we excluded those from the trial was because we were afraid that if a patient didn't respond to the systemic therapy that we were going to give them, they could really then develop severe neurological symptoms. So, for patient safety, we used 20 millimeters as the upper level for inclusion. Some of the other trials that I mentioned earlier also excluded patients with very large lesions. Now, in practice, one certainly can do Gamma Knife therapy to the large lesions and leave the smaller ones untreated. So I think it actually is very applicable to clinical practice. Dr. Davide Soldato Thank you very much for that insight, because I think that sometimes criteria for clinical trials, they have to be very restrictive. But then we know that in clinical practice, the applicability of these results is probably broader. So, going a little bit further in the results of the study, I just wanted a little bit of comment from you regarding what you saw in terms of intracranial response rate and duration of response among patients who obtained a response from the combination treatment. Dr. Harriet Kluger So we were actually surprised. When we first designed this study, as I said earlier, we weren't trying to beat out ipilimumab and nivolumab. We were really just trying to exclude those patients who wouldn't have otherwise been eligible for ipilimumab and nivolumab because of edema or possibly even previous radiation necrosis. So it was designed to differentiate between a response rate of 34%, and I believe the lower bound was somewhere in the 20s, because that's what we'd seen in the previous pembrolizumab study. What we saw in the first 20 patients that we enrolled was actually a response rate that far exceeded that. And so we enrolled another cohort to verify that result because we were concerned about premature publishing of a result that we might have achieved just by chance. The two cohorts were very similar in terms of the response rates. And certainly this still needs to be verified in a second study with additional institutions. We did include the Moffitt Cancer Center, and the response rate with Moffitt Cancer Center was very similar to the Yale Cancer Center response rate. Now, your other question was about duration of response. So the other thing that we started asking ourselves was whether this high response rate was really because the administration of the anti-VEGF will decrease the gadolinium enhancement and therefore we might actually just be seeing prettier scans but not tumor shrinkage. And the way to differentiate those two is by looking at the duration of the response. Median progression-free survival was 2.2 years. That's pretty long. The upper bound on the 95% confidence interval was not reached. I can't tell you that the duration is as good as the duration would be when you give ipilimumab. Perhaps it is less good. This was a fairly sick population of patients, and it included some who might not have been able to receive ipilimumab and nivolumab. So it provides an alternative. I do believe that we need to do a randomized trial where we compare it to ipilimumab and nivolumab, which is the current standard of care in this patient population. We do need to interpret these results with caution. I also want to point out regarding the progression-free survival that we only gave four doses of anti-VEGF. So one would think that even though anti-VEGF has a long half-life of three or four weeks, two years later, you no longer have anti-VEGF effect, presumably. So it does something when it's administered fairly early on in the course of the treatment. Dr. Davide Soldato So, in terms of clinical applicability, do you see this combination of pembrolizumab and bevacizumab - and of course, as we mentioned, this was a phase 2 trial. The number of patients included was not very high, but still you saw some very promising results when compared with the combination of ipilimumab and nivolumab. So do you see this combination as something that should be given particularly to those patients who might not be able to receive ipilimumab and nivolumab? So, for example, patients who are very symptomatic from the start or require a high dose of steroids, or also to provide a quicker response in terms of patients who have neurological symptoms, or do you think that someday it could be potentially used for all patients? Dr. Harriet Kluger The third part of your question, whether it can be used someday for all patients: I think we need to be very careful when we interpret these results. The study was substantially smaller than the ipilimumab/nivolumab trial that was conducted by Bristol Myers Squibb. Also going to point out that was a different population of patients. Those were all frontline patients. Here we had a mix of patients who'd had previous anti-CTLA-4 and frontline patients. So I don't think that we can replace ipilimumab and nivolumab with these results. But certainly the steroid-sparing aspect of it is something that we really need to take into consideration. A lot of patients have lesions in locations where edema can be dangerous, and some of them have a hard time coming off the steroids. So this is certainly a good approach for those folks. Dr. Davide Soldato And coming back to something that you mentioned in the very introduction, when you said that there were two main problems, which was one, the problem of the edema, and the second one, the problem of the radionecrosis. In your trial, there was a fair percentage of patients who received some type of local treatment before the systemic one. So the combination of pembrolizumab and bevacizumab. And most of the patients received radiosurgery. So I just wanted a brief comment regarding the incidence of radionecrosis in the trial and whether that specific component of the combination with bevacizumab was reduced. And how do you think that this fares in terms of what we see in clinical practice in terms of radionecrosis? Dr. Harriet Kluger I'm not sure that we really reduced the incidence of radiation necrosis. We saw radiation necrosis here. We saw less of it than in the trial of pembrolizumab monotherapy, but these were also different patients, different time. We saw more than we thought that we were going to see. It was 27%, I believe, which is fairly high still. We only gave the four doses of bevacizumab. Maybe to really prevent radiation necrosis, you have to continue to give the bevacizumab. That, too, needs to be tested. The reason that we gave the four doses of bevacizumab was simply because of the cost of the bevacizumab at the time. Dr. Davide Soldato Thank you very much for that comment on radionecrosis. And I really think that potentially this is a strategy, so continuing the bevacizumab, that really makes a lot of sense, especially considering that the tolerability of the regimen was really very, very good, and you didn't see any significant or serious adverse events related to bevacizumab. So just wondering if you could comment a little bit on the toxicities, whether you had anything unexpected. Dr. Harriet Kluger There was one patient who had a microperforation of a diverticulum, which was probably related to the bevacizumab. It was conservatively managed, and the patient did fine and actually remains alive now, many years later. We had one patient who had dehiscence of a previous wound. So there is some. We did not see any substantial hypertension, proteinuria, but we only gave the four doses. So it is possible that if you give it for longer, we would see some side effects. But still, relative to ipilimumab, it's very, very well tolerated. Dr. Davide Soldato Yeah, exactly. I think that the safety profile is really different when we compare the combination of ipilimumab/nivolumab with the pembrolizumab/bevacizumab. And as you said, this was a very small trial and probably we need additional results. But still, these results, in terms of tolerability and safety, I think they are very interesting. So one additional question that I think warrants a little bit of comment on your part is actually related to the presence of patients with BRAF mutation and, in general, to what you think would be the best course of treatment for these patients who present with the upfront brain metastases. So this, it's actually not completely related to the study, but I think that since patients with BRAF mutation were included, I think that this warrants a little bit of discussion on your part. Dr. Harriet Kluger So we really believe that long-term disease control, particularly in brain metastases, doesn't happen when you give BRAF/MEK inhibitors. You sometimes get long-term control if you've got oligometastatic disease in extracranial sites and if they've previously been treated with a lot of immune checkpoint inhibitors, which wasn't the case over here. So a patient who presents early in the course of the disease, regardless of their BRAF status, I do believe that between our studies and all the studies that have been done on immunotherapy earlier in the course of disease, we should withhold BRAF/MEK inhibitors unless they have overwhelming disease and we need immediate disease control, and then we switch them very quickly to immunotherapy. Can I also say something about the toxicity question from the bevacizumab? I have one more comment to make. I think it's important. We were very careful not to include patients who had overt hemorrhage from brain metastases. So melanoma brain metastases relative to other tumor types tend to bleed, and that was an exclusion criteria. We didn't see any bleeding that was attributable to the bevacizumab, but we don't know for sure that, if this is widely used, that that might not be a problem that's observed. So I would advise folks to use extreme caution and perhaps not use it outside of the setting of a clinical trial in patients with overt hemorrhage in the melanoma brain metastases. Dr. Davide Soldato Thank you very much. I think that one aspect that is really interesting in the trial is actually related to the fact that you collected a series of biomarkers, both circulating ones, but also some that were collected actually from the tissue. So just wondering if you could explain a little bit which type of biomarkers you evaluated and whether you saw any significant results that could suggest higher or lower efficacy of the combination. Dr. Harriet Kluger Thank you for that. So yes, the biomarker studies are fairly exploratory, and I want to emphasize that we don't have anything that's remotely useful in clinical practice at this juncture. But we did see an association between vessel density in the tumors and improved response to this regimen. So possibly those lesions that are more vascular are more fed by or driven by VEGF, and that could be the reason that there was improved response. We also saw that when there was less of an increase in circulating angiopoietin-2 levels, patients were more likely to respond. Whether or not that pans out in larger cohorts of patients remains to be determined. Dr. Davide Soldato Still, do you envision validation of these biomarkers in a potentially additional trial that will evaluate, again, the combination? Because I think that the signals were quite interesting, and they really make sense from a biological point of view, considering the mechanism of action of bevacizumab. So I think that, yeah, you're right, they are exploratory. But still, I think that there is very strong biological rationale. So really I wanted to congratulate you on including that specific part and on reporting it. And so the question is, really, do you envision validation of these biomarkers in larger cohorts? Dr. Harriet Kluger I would hope to see that, just as I'd like to see validation of the clinical results as well. The circulating biomarkers are very easy to do. It's a simple ELISA test. And the vessel density on the tumor is essentially CD34 staining and units per area of tumor. Also very simple to do. So I'd love to see that happen. Dr. Davide Soldato Do you think that considering the quality of the MRI that we are using right now, it would be possible to completely bypass even the evaluation on the tissue? Like, are we going in a direction where we can, at a certain point, say the amount of vessels that we see in these metastases is higher versus lower just based on MRI results? Dr. Harriet Kluger You gave me an outstanding idea for a follow-up study. I don't know whether you can measure the intensity of gadolinium as a surrogate, but certainly something worth asking our neuroradiology colleagues. Excellent idea. Thank you. Dr. Davide Soldato You're welcome. So just moving a step further, we spoke a lot about the validation of these results and the combination. And just wanted your idea on what do you think it would be more interesting to do: if designing a clinical trial that really compares pembrolizumab/bevacizumab with ipilimumab and nivolumab or going directly for the triplet. So we know that there has been some type of exploration of triplet combination in metastatic melanoma. So just your clinical impression: What would you do as an investigator? Dr. Harriet Kluger So it's under some discussion, actually. It's very difficult to compare drugs from different companies in an investigator-initiated trial. Perhaps our European colleagues can do that trial for us. In the United States, it's much harder, but it can be done through the cooperative groups, and we are actually having some discussions about that. I don't have the answer for you. It would be lovely to have a trial that compared the three drugs to ipi/nivo and to pembrolizumab/bevacizumab. So a three-arm trial. But remember, these are frontline melanoma patients. There aren't that many of them anymore like there used to be. So accrual will be hard, and we have to be practical. Dr. Davide Soldato Yeah, you're right. And in the discussion of the manuscript, you actually mentioned some other trials that are ongoing, especially one that is investigating the combination of pembro and lenvatinib, another one that is investigating the combination of nivolumab and relatlimab. So just wondering, do you think that the molecule in terms of VEGF inhibition, so bevacizumab versus lenvatinib, can really make a difference or is going to be just a mechanism of action? Of course, we don't have the results from this trial but just wondering if you could give us a general comment or your opinion on the topic. Dr. Harriet Kluger So that's a really great question. The trial of pembrolizumab and lenvatinib was our answer to the fact that bevacizumab is not manufactured by the same company as pembrolizumab, and we're trying to give a practical answer to our next study that might enable us to take this approach further. But it does turn out from our preclinical studies that bevacizumab and VEGF receptor inhibition aren't actually the same thing in terms of the effects on the blood-brain barrier or the perilesional tumor microenvironment in the brain. And these studies were done in mice and in in vitro models. Very different effects. The lenvatinib has stronger effect on the tumors themselves, the tumor cells themselves, than the bevacizumab, which has no effect whatsoever. But the lenvatinib doesn't appear to tighten up that blood-brain barrier. Dr. Davide Soldato Thank you. I think that's very interesting, and I think it's going to be interesting to see also results of these trials to actually improve and give more options to our patients in terms of different mechanism of action, different side effects. Because in the end, one thing that we discussed is that some combination may be useful in some specific clinical situation while others cannot be applicable, like, for example, an all immunotherapy-based combination. Just one final comment, because I think that we focused a lot on the intracranial response and progression-free survival. You briefly mentioned this but just wanted to reinforce the concept. Did you see any differences in terms of intracranial versus extracranial response for those patients who also had extracranial disease with the combination of pembro and bevacizumab? Dr. Harriet Kluger So the responses were almost always concordant. There were a couple of cases that might have had a body response and not an intracranial response and vice-versa, but the vast majority had concordant response or progression. We do believe that it's a biological phenomenon. The type of tumor that tends to go to the brain is going to be the type of tumor that will respond to whatever the regimen is that we're giving. In the previous trial also, we saw concordance of responses in the body and the brain. Dr. Davide Soldato Thank you very much. Just to highlight that really the combination is worth pursuing considering that there was not so much discordant responses, and the results, even in a phase 2 trial, were very, very promising. So thank you again, Dr. Kluger, for joining us today and giving us a little bit of insight into this very interesting trial. Dr. Harriet Kluger Thank you for having me. Dr. Davide Soldato So we appreciate you sharing more on your JCO article titled "Phase 2 Trial of Pembrolizumab in Combination with Bevacizumab for Untreated Melanoma Brain Metastases," which gave us the opportunity to discuss current treatment landscape in metastatic melanoma and future direction in research for melanoma brain metastasis. If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

When is the right time to buy a home? For many, it's when they feel ready—personally and financially. But even then, timing the market, understanding future price direction, and interpreting shifting economic signals can complicate the decision. In this episode, we break down everything you need to know to make a confident, informed choice about buying a home in 2025.First, we examine the all-powerful & predominant force of interest rates. The Bank of Canada held steady in April, but with two more rate cuts expected in June and September, we could see the overnight rate drop to 2.25% by year-end. Variable-rate holders may feel relief by the fall, while fixed rates have remained mostly unchanged—making the 3.99% offers available now historically attractive, even if there's potential for further dips.But rates don't act alone. Sentiment plays a massive role. Despite consumer confidence hitting all-time lows, April brought a slight rebound—too soon to call it a trend. However, business sentiment continues to deteriorate, dragging down the Real Estate Outlook Index at its fastest pace since the 2022 rate shock. Sales volumes remain sluggish, and we don't expect a sharp bounce anytime soon.Real estate moves in cycles, and Vancouver's decades-long climb may be entering a slower phase. We revisit Toronto's 1989 peak, when prices fell 27% over seven years and took 22 years to recover in inflation-adjusted dollars. Could Vancouver follow a similar path after peaking in 2022? If so, prices may not reach those highs again until 2028 or later. Buying today means thinking long-term—and accepting that appreciation might not arrive on your timeline.Meanwhile, first-time buyers are getting older. In Canada, the average is now 33—up from 32 in the early '80s—while in Ontario it's hit 40. Surprisingly, Americans, with cheaper homes but more student debt, wait even longer (age 38 on average). What's driving Canadians to buy sooner? But supply is failing to keep up. March housing starts missed expectations by 14%, and condo construction is in freefall—down 45% from last year. Remove purpose-built rentals, and we're at 15-year lows. Ontario and BC, the provinces with the greatest need, are down 38% and 30% year-over-year. CMHC says we need 3.1 million more homes by 2030. At this rate, that's a pipe dream.On top of that, inventory levels are rising, especially in the pre-sale market. Vancouver could hit 3,500 unsold new condos by year-end—a 60% surge. With investor demand almost vanished (down from 50%, then 25% and now 7%!), developers are cancelling projects, and hundreds of homes won't break ground. Even with record immigration—Toronto just became North America's fastest-growing city—new supply is evaporating.We close with a mini-market update: May sales in Vancouver are trending at a six-year low (outside of COVID lockdowns), while inventory is at an 11-year high. Median prices are up slightly, but average prices are slipping. Could this be the inflection point?So… is now the right time to buy? That depends on your goals, your timeline, and your outlook. This episode delivers the data, trends, and insights to help you decide—with eyes wide open.Are you prepared to buy with the long-term in mind, even if prices don't rise during your ownership? Let's chat about it. _________________________________ Contact Us To Book Your Private Consultation:

Listen to #Pulse95Radio in the UAE by tuning in on your radio (95.00 FM) or online on our website: www.pulse95radio.com ************************ Follow us on Social. www.instagram.com/pulse95radio www.facebook.com/pulse95radio www.twitter.com/pulse95radio

Spokojení s životem ve svém regionu jsou čtyři z pěti Čechů, ukázal exkluzivní průzkum agentury MEDIAN pro Radiožurnál a ČRo Plus. Nejspokojenější jsou obyvatelé Vysočiny a jihu ČR, zato na severu Čech, provázaném s útlumem těžby a navazujícího průmyslu, jen každý třetí z pěti. Horší nabídku pracovních pozic pociťují také obyvatelé u hranic jednotlivých krajů. Jakou zkušenost mají politici s dotačními programy pro rozvoj zaostávajících regionů? A co různé kraje potřebují?

Spokojení s životem ve svém regionu jsou čtyři z pěti Čechů, ukázal exkluzivní průzkum agentury MEDIAN pro Radiožurnál a ČRo Plus. Nejspokojenější jsou obyvatelé Vysočiny a jihu ČR, zato na severu Čech, provázaného s útlumem těžby a navazujícího průmyslu, jen každý třetí z pěti. Horší nabídku pracovních pozic pociťují také obyvatelé u hranic jednotlivých krajů. Jakou zkušenost mají politici s dotačními programy pro rozvoj zaostávajících regionů? A co různé kraje potřebují?

In a new report from the Kem C. Gardner Policy Institute showed that Utah's median income is ranked high among other states and middle-income households are earning more on average. Despite this, Utahns are still feeling the pinch of rising prices. Phil Dean, Chief Economist from the Kem C. Gardner Institute joins the show to discuss these findings and if these numbers really matter to the average Utahn.

Send us a textThis week, Teko & McFlei break down Jae Tips' Jazz 9 release rollout, sharing their thoughts on how the weekend played out and the energy behind the drop. The fellas also talk about JD Sports' ultra-limited release of the Air Max 95 Neon "Big Bubble", which hit select shelves overseas and left U.S. fans watching from afar.Patta is stirring the pot again, with leaked images of the upcoming Neon Air Max 90 "Waves" creating buzz ahead of the official drop. The guys also tap into the growing conversation around tariffs and what they could mean for sneaker consumers moving forward.All this and much more on this week's episode of The Sneaker Dads Podcast!Support the show

What will the impact be now that the U.S. has one of the highest tariff rates in the world?Topics covered include:Why the Trump administration raised tariffsHow the last round of U.S. tariffs led to higher prices and lower economic growthFour ways the world remains close to record connectivityWho have been the winners and losers from global tradeWhat will be the impact of this trade warEpisode SponsorsDelete Me – Use code David20 to get 20% offInsiders Guide Email NewsletterGet our free Investors' Checklist when you sign up for the free Money for the Rest of Us email newsletterOur Premium ProductsAsset CampMoney for the Rest of Us PlusShow NotesThe economic consequences of Mr Trump – looking for clarity in the tariffs chaos by Neil Shearing—Capital EconomicsTariff rate, most favored nation, simple mean, all products (%)—World Bank GroupDonald Trump's tariffs will fix a broken system by Peter Navarro—The Financial TimesDHL Global Connectedness Tracker—DHLObjective Knowledge: An Evolutionary Approach by Karl R. Popper—Oxford University PressGDP per capita (constant 2015 US$)—World Bank GroupJOSEPH E. STIGLITZ, GLOBALIZATION AND ITS DISCONTENTS REVISITED: ANTI-GLOBALIZATION IN THE ERA OF TRUMP, NEW YORK: W.W. NORTON & COMPANY, 2018 by Lino Sau—Annals of the Fondazione Luigi EinaudiFIFTY YEARS OF GROWTH IN AMERICAN CONSUMPTION, INCOME, ANDWAGES by Bruce Sacerdote—National Bureau of Economic ResearchReal Median Household Income in the United States—FREDEmployed full time: Median usual weekly real earnings: Wage and salary workers: 16 years and over—FREDConsumer Price Index for All Urban Consumers: Food in U.S. City Average/Median Household Income in the United States—FREDTrump's Love for Tariffs Began in Japan's '80s Boom By Jim Tankersley and Mark Landler—The New York TimesRelated Episodes515: Tariffs and the Mar-a-Lago Accord: What Trump Really Wants516: What Trump Wants Part 2 – How Trade Deficits and Capital Flows Can Harm or Help Countries427: Did the Tariffs Work? The Trade War Five Years Later212: Trade Wars Increase Prices and PovertySee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textWashington County's real estate market has shifted to a more balanced position with 4.82 months of inventory, representing a 22% increase from last year, though slight downward pressure on pricing has resulted in only a 2% decrease in average sold prices.• Median sold price of $520,000 shows minimal change from last year at just 1.7% higher• Current 30-year fixed mortgage rate at 6.75%, down from 7.26% in January• Original list price to sold price ratio is 95.9%, indicating sellers are typically getting slightly less than asking• Days on market varies significantly by price point - homes between $400,000-$500,000 sell fastest at 51 days• Migration data shows buyers from areas with higher home values (California, Colorado) find Washington County prices reasonable• Housing market correlation with interest rates appears broken since 2022• Local economy shows greater diversity than pre-2008 recession when construction was 30% of economy• Current unemployment rate remains stable at around 3%Guest Branden DuCharme, CMT, Find Du Charme Wealth Management here:https://ducharmewealth.com/contact-us/Looking for a Real Estate expert? Find us here!https://realestate435.kw.com/www.wealth435.com https://linktr.ee/wealth435 Below are our wonderful friends!Find FS Coffee here:https://fscoffeecompany.com/Find Tuacahn Amphitheater here:https://www.tuacahn.org/Find Blue Form Media here:https://www.blueformmedia.com/#podcast #southernutah #investing #stgeorgeutah #realestate #435podcast #financialmarket #business #affordablehousing #afforadable [00:00:00] Intro.[00:00:48] Washington County Real Estate Overview.[00:08:33] Market Statistics and Current Trends.[00:18:32] Breaking Down Price Points and Days on Market.[00:27:46] The Conflict of Interest in Real Estate.[00:38:35] Home Value Comparisons Across States.[00:47:33] Employment Data and Economic Diversity.[00:57:46] Final Thoughts and Episode Wrap-Up.

How Is Living in Maine Different Than Visiting?Maine is one of the most beautiful states in the country—and if you've ever visited, you probably already know that. The rocky coastline, charming lobster shacks, peaceful lighthouses, and fresh ocean air make it an unforgettable vacation spot.But what's it really like to live in Maine?As a local Realtor who helps people Make Maine Your Home, I've had this conversation with countless clients—many of whom fell in love with Maine during a visit and are now wondering if they should make the leap.Spoiler alert: living in Maine is amazing, but it's a different experience from visiting. Here's what you need to know if you're considering the move.  1. The Pace of Life: Vacationland vs. RealityWhen you're here for a week, it's all about coastal drives, seafood feasts, and soaking in the scenery. But living here means experiencing the rhythm of Maine life—slower, more intentional, and deeply connected to nature.✅ Remote work is on the rise here—Maine had one of the highest rates in the country in 2023.✅ Life is peaceful, but expect longer drives for essentials, especially in rural areas.✅ Winters are no joke—think snow tires, plowing, and prepping for the power to go out!  2. Cost of Living: More Affordable Than You Think?Compared to neighboring states like Massachusetts or New Hampshire, Maine's real estate is surprisingly affordable.

The I Love CVille Show headlines: HUD Median Family Incomes Released Today CVille Area: $125,800 In 2025; $124,200 In 2024 Arlington/Alexandria/DC Area; $163,900 Median Anti-Tesla & Pro-Tesla Protests Saturday At Stonefield How Does UVA Rebuild Its Battered Brand? Charlottesville Business Brokers Has Cash Buyers R Odom Contract: $3.25M Base , 6 Yrs & Bonuses Joel Gardner, Chairman, Jefferson Council, (4/3) Read Viewer & Listener Comments Live On Air The I Love CVille Show airs live Monday – Friday from 12:30 pm – 1:30 pm on The I Love CVille Network. Watch and listen to The I Love CVille Show on Facebook, Instagram, Twitter, LinkedIn, iTunes, Apple Podcast, YouTube, Spotify, Fountain, Amazon Music, Audible, Rumble and iLoveCVille.com.

Home prices are falling fast in some prime real estate markets across the country while others remain stubbornly stuck. What's the defining factor between a stable housing market and one where sellers are actively cutting prices? Housing inventory! This metric defined the 2020 - 2022 run-up in home prices, but the rubber band of demand is snapping back as buyer power grows, housing inventory rises, and investors get even better buying opportunities. Remember when people said, “I'll buy when prices drop”? Well, now might be the time. ResiClub's Lance Lambert joins us to provide a holistic view of housing inventory, prices, demand, and emerging opportunities. Lance walks through the most up-to-date data on where housing inventory is rising fast, where prices are quickly declining, and which markets are holding on as sellers remain in control. We'll also talk about why homebuilding costs are about to JUMP and the reason Warren Buffett sold his homebuilding stocks shortly after buying them. Will construction slow down, limiting new inventory and leading us back into ultra-low supply? If so, this could push home prices higher, creating a prime opportunity for real estate investors. In This Episode We Cover US real estate markets seeing the most and least new inventory, and where prices are falling  Is spiking inventory a worrying sign for the housing market, or are we merely normalizing? What to look at in your housing market to forecast whether prices will rise or fall  Why are homebuilding costs about to JUMP, and could this lead to even more inventory problems? The new housing trend: Older renters, but could this mean more demand for rentals? And So Much More! Links from the Show Join the Future of Real Estate Investing with Fundrise Join BiggerPockets for FREE Sign Up for the On the Market Newsletter Find an Investor-Friendly Agent in Your Area Dave's BiggerPockets Profile ResiClub: The cost breakdown for constructing a single-family home in 2024 ResiClub: Did Warren Buffett see this coming? Homebuilder margins face pressure in 2025 ResiClub: The vanishing young homebuyer: Median first-time homebuyer age jumps from 28 in 1991 to 38 in 2024 Inventory Is Key to a Stable Real Estate Market—Will It Recover? Join Lance's Newsletter Grab Dave's Book, “Real Estate by the Numbers” Jump to topic: (0:00) Intro  (1:27) Hottest and Coldest Markets  (8:00) Should We Be Worried?  (11:00) Where Prices Are Dropping  (14:54) What to Look For In YOUR Market  (17:39) Homebuilding Costs To JUMP  (21:48) Developer Profits Shrink  (24:11) Older Renters, Better for Investors Check out more resources from this show on BiggerPockets.com and https://www.biggerpockets.com/blog/on-the-market-308 Interested in learning more about today's sponsors or becoming a BiggerPockets partner yourself? Email advertise@biggerpockets.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Cancer is one of the most terrifying illnesses of our age - a sudden change that happens silently inside our bodies and slowly eats away at us until there's nothing left. It's also one of the biggest failures of the pharmaceutical age - somewhere between 90 and 97% of all cancer drugs fail at clinical trials. Which is why we're unbelievably excited to bring you our conversation with Dr. Thomas Seyfried, Professor of Biology at Boston College who appears to be hot on the trail of a cure cancer that has nothing to do with the oncology-industrial-complex. According to the dozens of papers he and his colleagues have published over the last few decades, a strict ketogenic diet coupled to a glutamine inhibitor is sufficient to weaken cancer cells to the point that the immune system can actually clear the tumor. A recent paper from his group published in February of 2025 shows the stunning effects of his protocol in a small group of eighteen glioblastoma patients. Median survival for these patients for the last hundred years has been 12-15 months, but with Seyfried's intervention appears to have been extended up to 84 months. That's seven years, for those keeping score.We sit down with Seyfried to take apart his protocol, why it works for cancer, why no one's heard if it, and how everyone has completely misunderstood what cancer actually is.MAKE HISTORY WITH US THIS SUMMER:https://demystifysci.com/demysticon-2025PATREON https://www.patreon.com/c/demystifysciPARADIGM DRIFThttps://demystifysci.com/paradigm-drift-show(00:00) Go!(00:07:33) - Reception of Metabolic Cancer Research(00:10:05) - Breakthrough in Glioblastoma Treatment(00:14:49) - Glutamine-Glutamate Cycle in Cancer(00:16:33) - Challenges and Critiques of Standard Care(00:17:43) - Barriers to Implementing Metabolic Therapies(00:24:19) - Radiation and Cancer Treatment(00:26:07) - Metabolic Approach to Cancer(00:27:30) - Evolutionary Biology's Role in Understanding Cancer(00:28:52) - Mitochondria's Role in Cellular Destiny(00:31:39) - The Oxidative Phosphorylation Process(00:35:28) - Cancer and Mitochondrial Function(00:38:43) - Cellular Electrochemical Gradients(00:41:30) - Cancer's Dependency on Fermentable Fuels(00:45:08) - Glutamine's Role in Cancer Treatment(00:52:11) - Patient Compliance and Dietary Challenges(00:55:33) - Glucose Ketone Index for Health Monitoring(01:06:48) - Fenbendazole and Cancer Research(01:10:02) - Medical Industry Business Models(01:13:27) - Diets and Nutritional Ketosis(01:17:06) - Metabolic Variability and Personalization(01:19:25) - Exercise and Metabolic Health(01:23:43) - Historical Misconceptions in Cancer Treatment(01:26:21) - Obesity and Cancer Prevention(01:28:00) - Metabolic Theories of Cancer(01:47:18) - Metastatic Cancer Origins(01:55:24) - Therapeutic and Collaborative Approaches(01:59:57) - Practical Steps and Transformations#CancerResearch, #glioblastoma, #CancerAwareness, #Oncology, #CancerTreatment, #CancerSurvivor, #FightCancer, #EndCancer, #CancerSupport, #ClinicalTrials, #CancerWarrior, #BeatCancer, #CureCancer, #CancerFighter, #StayStrong, #CancerCommunity, #philosophypodcast, #sciencepodcast, #longformpodcast ABOUS US: Anastasia completed her PhD studying bioelectricity at Columbia University. When not talking to brilliant people or making movies, she spends her time painting, reading, and guiding backcountry excursions. Shilo also did his PhD at Columbia studying the elastic properties of molecular water. When he's not in the film studio, he's exploring sound in music. They are both freelance professors at various universities. SOCIAL: - Discord: https://discord.gg/MJzKT8CQub- Facebook: https://www.facebook.com/groups/DemystifySci- Instagram: https://www.instagram.com/DemystifySci/- Twitter: https://twitter.com/DemystifySciMUSIC: -Shilo Delay: https://g.co/kgs/oty671

Home prices are falling fast in some prime real estate markets across the country while others remain stubbornly stuck. What's the defining factor between a stable housing market and one where sellers are actively cutting prices? Housing inventory! This metric defined the 2020 - 2022 run-up in home prices, but the rubber band of demand is snapping back as buyer power grows, housing inventory rises, and investors get even better buying opportunities. Remember when people said, “I'll buy when prices drop”? Well, now might be the time. ResiClub's Lance Lambert joins us to provide a holistic view of housing inventory, prices, demand, and emerging opportunities. Lance walks through the most up-to-date data on where housing inventory is rising fast, where prices are quickly declining, and which markets are holding on as sellers remain in control. We'll also talk about why homebuilding costs are about to JUMP and the reason Warren Buffett sold his homebuilding stocks shortly after buying them. Will construction slow down, limiting new inventory and leading us back into ultra-low supply? If so, this could push home prices higher, creating a prime opportunity for real estate investors. In This Episode We Cover: Is spiking inventory a worrying sign for the housing market, or are we merely normalizing? What to look at in your housing market to forecast whether prices will rise or fall  Why are homebuilding costs about to JUMP, and could this lead to even more inventory problems? The new housing trend: Older renters, but could this mean more demand for rentals? And So Much More! Links from the Show Join BiggerPockets for FREE Let Us Know What You Thought of the Show! Ask Your Question on the BiggerPockets Forums BiggerPockets YouTube Apply to Be a BiggerPockets Real Estate Guest ResiClub: The cost breakdown for constructing a single-family home in 2024 ResiClub: Did Warren Buffett see this coming? Homebuilder margins face pressure in 2025 ResiClub: The vanishing young homebuyer: Median first-time homebuyer age jumps from 28 in 1991 to 38 in 2024 Invest in Private Market Real Estate with the Fundrise Flagship Fund Grab Dave's Book, “Real Estate by the Numbers” Sign Up for the BiggerPockets Real Estate Newsletter Find an Investor-Friendly Agent in Your Area Inventory Is Key to a Stable Real Estate Market—Will It Recover? Join Lance's Newsletter Connect with Dave Check out more resources from this show on BiggerPockets.com and https://www.biggerpockets.com/blog/real-estate-1101 Interested in learning more about today's sponsors or becoming a BiggerPockets partner yourself? Email advertise@biggerpockets.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

(2:09) Sote-säästöt julkaistiin lopulta — mikä vaikutus? (17:48) Demarien linja, perusteltua vai oma maali? (24:36) EVA:n mielipidekysely suomalaisista medioista (30:16) Parhaat ryhmäviestit

The Bureau of Labor Statistics released data on the median salaries of Americans, revealing a significant gap between what people earn and what they feel is necessary to live comfortably. In this episode, Art shares his thoughts on the findings and offers tips for cultivating a content heart.Resources: 8 Money MilestonesAsk a Money Question!

In this episode of the Primal Potential Podcast, we're diving into three powerful but simple strategies to help you optimize your blood sugar, improve your insulin sensitivity, and increase your energy levels. These are real-world, easy-to-implement hacks that go beyond the usual “eat less sugar” advice. Before we get started, grab your copy of my new Fat Loss E-Book! Here's the link. And, head over to my new YouTube channel to subscribe and turn on notifications before the new Carb Series kicks off next week.  Hack #1: Get Sunlight First Thing in the Morning ☀️ Did you know that getting direct sunlight within the first hour of waking helps reset your circadian rhythm, which plays a major role in blood sugar regulation and insulin sensitivity? Pairing this with light movement (like a 10-minute walk or some gentle stretching) can improve how efficiently your body uses glucose before breakfast. What the Science Says: On average, exposure to sunlight improved insulin sensitivity by 18.75%. Median improvement was 18%, meaning half of people experienced even greater benefits. Range of effects: Sunlight exposure improved insulin function by 15-22%. Glucose tolerance: Participants who got more sunlight saw a 12-16% improvement in how well their bodies processed carbohydrates.

Today, as part of our “Tricks of the Trade” series, we’re at the Houston Livestock Show and Rodeo, where students put goats and lambs up for sale to the highest bidder. Here, livestock auctions generate a pile of philanthropic money for a Texas scholarship fund, and the bids go up and up and up. But first: Air travel is in a snarl today with a power outage at London’s Heathrow Airport.

Today, as part of our “Tricks of the Trade” series, we’re at the Houston Livestock Show and Rodeo, where students put goats and lambs up for sale to the highest bidder. Here, livestock auctions generate a pile of philanthropic money for a Texas scholarship fund, and the bids go up and up and up. But first: Air travel is in a snarl today with a power outage at London’s Heathrow Airport.

How do local Indianapolis Real Estate Investors compete in an increasingly competitive market? The Home Value growth in Indianapolis is 42% since 2020. The Median home price in 2020 was$170,000, but it has increased to $240,000. 2%-4% mortgage rates have risen to 8%.Many people are leaving bigger cities for more affordable living in Indiana. Large Out-of-State corporate investors are swooping in to grab up single-family homes and apartments. Competition for finding good real estate deals is increasingly hard to come by. It's like a gold rush in Indiana.But there is hope for success in Indy for wholesalers and other local investors. Partly, it does take a bit of extra work digging twice as hard as we've been used to. Some of us have gotten lazy, taking the easy deals for granted. But there are deals out there.Local investors and wholesalers have a lot of advantages compared to out-of-state buyers. Many out of state buyers have been developing bad reputations. This is where local investors with consistent track records and face to face encounters goes a long way.Out of State buyers may be able to offer more money, and sometimes that's what it comes down to. But local buyers can offer trust, as many sellers are getting burned by corporate conglomerates. And many out of state investors are coming for 6-12 months and then packing up and leaving. For those local buyers sticking around, consistency builds your credibility.It's not about making big adjustments for buyers right now. It's about make small ones. Maybe you can safely buy at a little higher ARV percentage than you used to be able. Maybe you need to attend more Meet-Ups and other events to make a few extra connections that get you that deal. Maybe you just need to have your ducks lined up better for financing to be a little bit quicker to get the deal when available, so you can close faster. Maybe it's exploring new areas that will be the next Fountain Square. Maybe doing delayed flips and continuing to rent for a few years is a successful recipe as properties appreciate.The moral of the story is, those investors who are in the Indianapolis area for the long-term are the ones who will eventually win out in the end. In the mean time, listen to Brett & Ronnie discuss some tips and tactics that could help you in your short game at this season of the real estate market.

Send us a textJim dives into the latest National Association of Realtors Profile of Homebuyers and Sellers, revealing critical data points to help real estate professionals target their marketing efforts more effectively. Highlights From the Profile of Home Buyers and Sellers The demographic trends show significant shifts in buyer age and preferences that create new opportunities for agents who understand these changes.• First-time buyer share decreased to 24% of market, lowest since NAR began collecting data in 1981• Median first-time buyer age increased to 38 years, repeat buyer age rose to 61 years• 86% of all buyers utilized a real estate agent• 77% of buyers interviewed only one agent before deciding• 40% of buyers found their agent through a friend, neighbor, or relative• Online photos (41%) were rated as the most valuable content when searching for homes• Typical home seller age reached 63 years, with median ownership of 10 years• FSBOs sold for $55,000 less on average than agent-represented homes• Modern kitchens with islands (60%), home offices, and energy efficiency features are high priorities• Millennials (25-43) represent the largest buying group at 38% of purchasesFor questions about home inspections or to learn how Habitation Investigation helps real estate agents close more deals, call us or visit homeinspectionsinohio.com.Support the showTo learn more about Habitation Investigation, the Two-time Winner of the Best Home Inspection Company in the Midwest Plus the Winner of Consumer Choice Award for Columbus Ohio visit Home Inspection Columbus Ohio - Habitation Investigation (homeinspectionsinohio.com) Continuing Education for Ohio Agents Scheduled classes Continuing Education for Ohio Agents Course listingsFacebook Page FacebookFor home buyers: What to expect from a home inspection. YT video for home buyersHome Buyer and Seller Resources | Habitation Investigation Heartland Commercial Property InspectionsIf you would like to be a guest on the podcast contact us and let us know. You can visit Home (jimtroth.com) and go to the podcast page or message Habitation Investigation.

We are in a NEUTRAL MARKET! Median sold price in Leon county is $302000 - 3% more than 2024We are in a normal market!

Five Questions To Ask Before Moving To Maine | Living in Maine Thinking About Moving to Maine? Ask Yourself These 10 Questions First!

Ben and Nathan reassure a listener that an above median LSAT can carry your application, even with a less than stellar GPA. Read more on our website. Email daily@lsatdemon.com with questions or comments. Watch this episode on Youtube!

This week, we talk about median playtime, weapon balance, and revisiting our older games. From chaotic co-op antics to echolocation-based platforming, our game jam experiments were always a blast, even if they were never quite commercially viable. But hey, you make some games for players and some just for the joy of making them.Support Crashlands 2!Official Website: https://www.bscotch.net/games/crashlands-2/Trailer: https://www.youtube.com/watch?v=ib7fzLf59voSteam Wishlist: https://store.steampowered.com/app/1401730/Crashlands2/Google Play:https://play.google.com/store/apps/details?id=com.bscotch.crashlands2Apple: https://apps.apple.com/us/app/crashlands-2/id152819933100:32 Intro00:50 Thanks to our supporters! (https://moneygrab.bscotch.net)01:04 Crashlands 2 Beta18:29 Marketing24:22 Balancing weapons33:28 Giantmuskrat: Would you replay your older titles on https://bscotch.itch.io/ and give them a score on the nailed it/whiffed it scale?To stay up to date with all of our buttery goodness subscribe to the podcast on Apple podcasts (apple.co/1LxNEnk) or wherever you get your audio goodness. If you want to get more involved in the Butterscotch community, hop into our DISCORD server at discord.gg/bscotch and say hello! Submit questions at https://www.bscotch.net/podcast, disclose all of your secrets to podcast@bscotch.net, and send letters, gifts, and tasty treats to https://bit.ly/bscotchmailbox. Finally, if you'd like to support the show and buy some coffee FOR Butterscotch, head over to https://moneygrab.bscotch.net. ★ Support this podcast ★

Brad Hutchings returns to discuss AI. Pete A Turner of the Break It Down Show has been working to use AI in some of his projects. He tried to find the Median debut for all baseball players. He did the work to find Detroit Tiger phenom, Jim Proctor who today is the middle player in all players, based on debut date, in MLB history (per baseball reference). Pete Writes about Jim in an article on X. Brad and Pete discuss Grok's inability to find the median player. Pete tried a few other AIs...they just don't work this way. Brad notes that AIs will give loquacious answers, but the results are more fantasy than fact. Then a funny test happens...what happens when you ask an AI, while offline, to reference an online resource...well...AI does a performance of giving an answer. This is a fun one.

New data provided to RNZ by Corelogic shows just how much house prices have shot up since the turn of the century. In some parts of the country, the median price has increased 1000 percent over 25 years. Money correspondent Susan Edmunds spoke to Lisa Owen.

Jay and Ryan discuss what you should be doing to build your business this year and what should you NOT be doing, inflation comes in higher than expected, the median age of a renter skyrockets, and YouTube users are watching on their TV's now more than ever before.

Welcome to the "Saturday Morning Golf Stat" from the Hack it Out Golf Podcast. Today's episode brings us to new territory, as the TOUR's allows for more granular stats: how does green firmness affect how close a Tour pro can get to the pin? In this episode, Mark and Greg guess the median proximity for soft, medium, and hard greens. Lou brings the answer—and it will likely surprise you. How much difference do you think it makes? The guys then give a short discussion about how to make changes to your game to adjust to conditions so that you can shoot your best scores. Each of these will be a mini-episode (10-15 minutes long) about an interesting golf stat. We will discuss what you can learn, and most importantly, how you can apply this on the golf course to lower your scores and lower your handicap. Listen on your drive to the golf course or over your Saturday morning coffee! Data is sourced from Arccos Golf. They have over 1 BILLION shots in their database.  Check them out at: https://www.arccosgolf.com/  Use code MARK15 for 15% off! Learn more about your ad choices. Visit megaphone.fm/adchoices

Sheil Kapadia, Diante Lee, and Steven Ruiz kick off the show by reacting to Bill Belichick's proclamation that it's time to rename the Lombardi Trophy in Tom Brady's honor (00:00). Then, the guys discuss the floor, ceiling, and median outcomes for the Cowboys next season on the heels of the Brian Schottenheimer hire (03:02). Then, they do the same for the Raiders following their decision to bring in Pete Carroll (25:22). To round out the show, they take a look at potential offseason QB moves, how the Lions will fare without Ben Johnson (51:38), rumors of Kellen Moore to New Orleans (54:24), and some early thoughts on next weekend's Super Bowl matchup between the Chiefs and Eagles (59:58). The Ringer is committed to responsible gaming. Please visit www.rg-help.com to learn more about the resources and helplines available. Hosts: Sheil Kapadia, Diante Lee, and Steven Ruiz Producer: Troy Farkas Learn more about your ad choices. Visit podcastchoices.com/adchoices

Thank you for joining us for our 2nd Cabral HouseCall of the weekend! I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks… Jenny: Hi Dr. Cabral, First, thank you to you and your amazing team for selflessly giving of your time and knowledge so we can all learn and grow on our health journeys. We can't really express this enough. I have a question about your Alkalizing Vitamin C product. You've recommended this as something to take in water upon waking, but could it also be effective when I add it to my morning smoothie or is it better to take separately? I don't enjoy the taste on its own, so I'm unlikely to drink it just in water. Any suggestions? Thanks!   Kavita: Hello Dr. Cabral, First, I want to thank you for your amazing work! I listen to your podcast every day, which means I've been consistently listening for the past 3,231 days! :) I have an important question for you. I recently started taking Berberine, but a friend mentioned that it may have adverse reactions. She told me about her neighbor, who had to stop taking it because doctors wouldn't perform surgery on her while she was using Berberine. I'm unsure of the exact details, but it raised some concerns. I started taking Berberine because there's diabetes in my family, and I'm hoping to avoid getting on any medications as I move ahead in life. How do I make sure it is working for me? I hope this gets on your list soon :) Thank you, Kavita ( Pronounced - ka-vee-tha)    Jenni: Hi, I've been battling Meibomian Gland Disorder for over a year. The only thing that has provided relief has been taking 50mg daily of doxycycline. I've been on this dosage for 10 months. My doctor has tried weaning me off, but the symptoms pop back up after 4-5 days. Nobody seems to understand why this issue arose suddenly, and no one can offer me help outside of antibiotics. Do you have any experience in helping patients with MGD? Could this be due to heavy metals, gut issues, systemic inflammation? I'm desperate for natural relief. Thank you, Jenni   Michael: Hi Dr. Cabral. Thank you for the work you do and especially taking time to answer people's questions. My question is regarding to home oil as the main heating source. What are your thoughts on the cleanest and safest option? We currently have the standard heating oil. There is an option to change the oil to a B50 blend which consists of a 50/50 blend of standard heating oil and biodiesel. This would then convert to a B99 fuel which is 99% biodiesel. Any thoughts on this subject or know of a place I can go to research more? Thank you!   Paedyn: Hi Dr Cabral, but of a hard to question. What are some ways I can naturally treat MALS (median arcuate ligament syndrome). I woke up randomly with stomach pain in my epigastric region one day out of nowhere and Dr's are saying it's this and that the only treatment option is very major surgery which only a select handful of surgeons perform this surgery worldwide and a lot of people end up worse off after the surgery. I just want to heal my body naturally. Thank you so much! Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right! - - - Show Notes and Resources: StephenCabral.com/3264 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!